NYSE:DVA DaVita (DVA) Stock Price, News & Analysis $173.14 -1.08 (-0.62%) Closing price 03:59 PM EasternExtended Trading$172.61 -0.53 (-0.31%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About DaVita Stock (NYSE:DVA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get DaVita alerts:Sign Up Key Stats Today's Range$172.78▼$176.6950-Day Range$173.82▼$194.6352-Week Range$101.00▼$247.49Volume455,029 shsAverage Volume887,527 shsMarket Capitalization$10.89 billionP/E Ratio12.75Dividend YieldN/APrice Target$235.86Consensus RatingModerate Buy Company Overview DaVita Inc. is a healthcare provider focused on kidney care. Its core business is operating outpatient dialysis centers that provide treatment and related services to people with chronic kidney failure. The company also offers home dialysis programs, provides dialysis services to patients in hospitals, and supports kidney care through services such as care coordination and education. DaVita primarily serves patients in the United States and also operates in international markets. Founded in 1994 as Total Renal Care, the company adopted the name DaVita in 2000. Its chief executive officer is Javier Rodriguez, who has led the company since 2019.AI Generated. May Contain Errors. Read More DaVita Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks90th Percentile Overall ScoreDVA MarketRank™: 4.480450629555 of 5 starsDaVita scored higher than 90% of companies evaluated by MarketBeat, and ranked 30th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingDaVita has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 4 buy ratings, 3 hold ratings, and no sell ratings.Upside PotentialDaVita has a consensus price target of $235.86, representing about 36.4% upside from its current price of $172.91.Amount of Analyst CoverageDaVita has only been the subject of 4 research reports in the past 90 days.Read more about DaVita's stock forecast and price target. Earnings and Valuation4.4 / 5Proj. Earnings Growth18.28% Earnings GrowthEarnings for DaVita are expected to grow by 18.28% in the coming year, from $14.66 to $17.34 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DaVita is 12.73, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.98.Price to Earnings Ratio vs. SectorThe P/E ratio of DaVita is 12.73, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.16.Price to Earnings Growth RatioDaVita has a PEG Ratio of 0.44. PEG Ratios below 1 indicate that a company could be undervalued.Read more about DaVita's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.33% of the float of DaVita has been sold short.Short Interest Ratio / Days to CoverDaVita has a short interest ratio ("days to cover") of 5.14.Change versus previous monthShort interest in DaVita has recently increased by 4.82%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDaVita does not currently pay a dividend.Dividend GrowthDaVita does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.49 News SentimentDaVita has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 12 news articles for DaVita this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for DVA on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows2 people have added DaVita to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, DaVita insiders have not sold or bought any company stock.Percentage Held by Insiders1.90% of the stock of DaVita is held by insiders.Percentage Held by Institutions90.12% of the stock of DaVita is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about DaVita's insider trading history. Receive DVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DaVita and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DVA Stock News HeadlinesDaVita Expands Availability Of Expanded Hemodialysis Therapy To Every U.S. Center3 hours ago | marketscreener.comMDaVita Expands Availability of Advanced Dialysis Therapy to Every U.S. CenterNovember 17 at 6:00 AM | prnewswire.comBitcoin's problem is its own sizeBitcoin is trading near $60,000. For your Bitcoin position to double from here, roughly $1.5 trillion in new money has to flow into a single asset. Not impossible. Now ask what it takes to move a coin with a $40 million market cap. Not a trillion dollars. A fraction of a percent of one. That's the entire reason my team stopped hunting for the next Bitcoin years ago. I put together a short presentation walking through where we're looking instead, and why the largest percentage moves in this market stopped coming from the coins everyone recognizes.November 17 at 1:00 AM | Crypto 101 Media (Ad)DaVita Earnings Call Highlights Growth, Costs and GuidanceNovember 15 at 10:42 PM | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and DaVita (DVA)November 13, 2026 | theglobeandmail.comIs Wall Street bullish or bearish on DaVita stock?November 13, 2026 | msn.comDVA Investors Have Opportunity to Join DaVita Inc. Fraud Investigation with SBS LawNovember 12, 2026 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVANovember 12, 2026 | prnewswire.comSee More Headlines DVA Stock Analysis - Frequently Asked Questions How have DVA shares performed this year? DaVita's stock was trading at $113.74 at the beginning of 2026. Since then, DVA shares have increased by 52.0% and is now trading at $172.91. How were DaVita's earnings last quarter? DaVita Inc. (NYSE:DVA) posted its quarterly earnings results on Thursday, October, 29th. The company reported $3.82 earnings per share for the quarter, beating the consensus estimate of $3.57 by $0.25. The business's revenue was up 4.6% compared to the same quarter last year. Read the conference call transcript. Does DaVita have any subsidiaries? DaVita subsidiaries include Northwest Physicians Network, Purity Dialysis, Family Health Care of Central Florida, Healthcare Partners, Gambro Healthcare, Aberdeen Dialysis LLC, Accountable Kidney Care LLC, and others. Who are DaVita's major shareholders? DaVita's top institutional shareholders include State Street Corp (2.19%), Goldman Sachs Group Inc. (0.59%), First Trust Advisors LP (0.22%) and Teachers Retirement System of The State of Kentucky (0.20%). Insiders that own company stock include Javier Rodriguez, Michael David Staffieri, Joel Ackerman, Kathleen Alyce Waters, James O Hearty and Barbara J Desoer. View institutional ownership trends. How do I buy shares of DaVita? Shares of DVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of DaVita own? Based on aggregate information from My MarketBeat watchlists, some other companies that DaVita investors own include Tesla (TSLA), NVIDIA (NVDA), Bank of America (BAC), Bristol Myers Squibb (BMY), Walt Disney (DIS), AbbVie (ABBV) and Intel (INTC). Company Calendar Last Earnings10/29/2026Today11/17/2026Fiscal Year End12/31/2026Next Earnings (Estimated)2/01/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 DVA's financial health is in the Red zone, according to TradeSmith. DVA has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryHealthcare Services Current SymbolNYSE:DVA CIK927066 Webwww.davita.com Phone(310) 536-2668Fax302-636-5454Employees78,000Year Founded1994Price Target and Rating Average Price Target for DaVita$235.86 High Price Target$287.00 Low Price Target$215.00 Potential Upside/Downside+35.9%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$13.58 Trailing P/E Ratio12.77 Forward P/E Ratio10.01 P/E Growth0.44Net Income$746.80 million Net Margins6.49% Pretax Margin10.71% Return on Equity-225.93% Return on Assets5.42% Debt Debt-to-Equity RatioN/A Current Ratio1.41 Quick Ratio1.36 Sales & Book Value Annual Sales$13.64 billion Price / Sales0.80 Cash Flow$21.67 per share Price / Cash Flow8.01 Book Value($5.70) per share Price / Book-30.45Miscellaneous Outstanding Shares62,900,000Free Float61,705,000Market Cap$10.92 billion OptionableOptionable Beta0.87 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NYSE:DVA) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredBitcoin's problem is its own sizeBitcoin is trading near $60,000. For your Bitcoin position to double from here, roughly $1.5 trillion in new m...Crypto 101 Media | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DaVita Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DaVita With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.